CRDL vs. NVDA

Last updated Apr 2, 2026

Compare and contrast key facts about Cardiol Therapeutics Inc Class A (CRDL) and NVIDIA Corporation (NVDA).

Performance

CRDL vs. NVDA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Cardiol Therapeutics Inc Class A (CRDL) and NVIDIA Corporation (NVDA). The values are adjusted to include any dividend payments, if applicable.

CRDL vs. NVDA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019
CRDL Cardiol Therapeutics Inc Class A	46.78%	-25.48%	51.80%	65.33%	-72.43%	-15.14%	-38.35%	-5.49%
NVDA NVIDIA Corporation	-5.76%	38.92%	171.25%	239.02%	-50.26%	125.48%	122.30%	57.62%

Fundamentals

Market Cap CRDL : $118.62M NVDA : $4.29T
EPS CRDL : -$0.39 NVDA : $4.90
PB Ratio CRDL : 12.41 NVDA : 27.30
Total Revenue (TTM) CRDL : $0.00 NVDA : $215.94B
Gross Profit (TTM) CRDL : -$33.70K NVDA : $153.46B
EBITDA (TTM) CRDL : -$31.64M NVDA : $144.55B

Returns By Period

In the year-to-date period, CRDL achieves a 46.78% return, which is significantly higher than NVDA's -5.76% return.

CRDL

• 1D: 3.70%
• 1M: 37.25%
• YTD: 46.78%
• 6M: 30.84%
• 1Y: 50.93%
• 3Y*: 42.16%
• 5Y*: -16.79%
• 10Y*: —

NVDA

• 1D: 0.77%
• 1M: -3.68%
• YTD: -5.76%
• 6M: -6.13%
• 1Y: 59.59%
• 3Y*: 85.01%
• 5Y*: 66.40%
• 10Y*: 69.75%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

CRDL vs. NVDA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CRDL

CRDL Risk / Return Rank: 63
CRDL Sharpe Ratio Rank: 65
CRDL Sortino Ratio Rank: 66
CRDL Omega Ratio Rank: 62
CRDL Calmar Ratio Rank: 63
CRDL Martin Ratio Rank: 57

NVDA

NVDA Risk / Return Rank: 82
NVDA Sharpe Ratio Rank: 83
NVDA Sortino Ratio Rank: 80
NVDA Omega Ratio Rank: 77
NVDA Calmar Ratio Rank: 86
NVDA Martin Ratio Rank: 84

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CRDL vs. NVDA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Cardiol Therapeutics Inc Class A (CRDL) and NVIDIA Corporation (NVDA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	CRDL	NVDA	Difference
Sharpe ratio Return per unit of total volatility	0.71	1.45	-0.74
Sortino ratio Return per unit of downside risk	1.48	2.14	-0.66
Omega ratio Gain probability vs. loss probability	1.18	1.27	-0.09
Calmar ratio Return relative to maximum drawdown	1.11	3.08	-1.96
Martin ratio Return relative to average drawdown	1.70	7.73	-6.03
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

CRDL vs. NVDA - Sharpe Ratio Comparison

The current CRDL Sharpe Ratio is 0.71, which is lower than the NVDA Sharpe Ratio of 1.45. The chart below compares the historical Sharpe Ratios of CRDL and NVDA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	CRDL	NVDA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.71	1.45	-0.74
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.19	1.29	-1.48
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	1.40	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.15	0.61	-0.76

Correlation

The correlation between CRDL and NVDA is 0.21, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

CRDL vs. NVDA - Dividend Comparison

CRDL has not paid dividends to shareholders, while NVDA's dividend yield for the trailing twelve months is around 0.02%.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
CRDL Cardiol Therapeutics Inc Class A	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
NVDA NVIDIA Corporation	0.02%	0.02%	0.03%	0.03%	0.11%	0.05%	0.12%	0.27%	0.46%	0.29%	0.45%	1.20%

Drawdowns

CRDL vs. NVDA - Drawdown Comparison

The maximum CRDL drawdown since its inception was -92.71%, roughly equal to the maximum NVDA drawdown of -89.72%. Use the drawdown chart below to compare losses from any high point for CRDL and NVDA.

Drawdown Indicators

	CRDL	NVDA	Difference
Max Drawdown Largest peak-to-trough decline	-92.71%	-89.72%	-2.99%
Max Drawdown (1Y) Largest decline over 1 year	-39.87%	-20.21%	-19.66%
Max Drawdown (5Y) Largest decline over 5 years	-90.72%	-66.34%	-24.38%
Max Drawdown (10Y) Largest decline over 10 years	—	-66.34%	—
Current Drawdown Current decline from peak	-77.38%	-15.10%	-62.28%
Average Drawdown Average peak-to-trough decline	-68.75%	-36.40%	-32.35%
Ulcer Index Depth and duration of drawdowns from previous peaks	26.13%	8.05%	+18.08%

Volatility

CRDL vs. NVDA - Volatility Comparison

Cardiol Therapeutics Inc Class A (CRDL) has a higher volatility of 22.51% compared to NVIDIA Corporation (NVDA) at 10.43%. This indicates that CRDL's price experiences larger fluctuations and is considered to be riskier than NVDA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	CRDL	NVDA	Difference
Volatility (1M) Calculated over the trailing 1-month period	22.51%	10.43%	+12.08%
Volatility (6M) Calculated over the trailing 6-month period	42.25%	25.79%	+16.46%
Volatility (1Y) Calculated over the trailing 1-year period	72.73%	41.42%	+31.31%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	87.47%	51.72%	+35.75%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	87.63%	49.84%	+37.79%

Financials